Question 1

Can you actually buy IGF-1?

Accepted Answer

Two answers, and each belongs to a different object. One version has a prescription behind it. Injectable recombinant human (rh)IGF-I (mecasermin) has been available for nearly 20 years for treatment of the rare instances of GH insensitivity caused by GH receptor defects or GH-inhibiting antibodies. GH insensitivity means a body that makes growth hormone but cannot respond to it. A pharmacy dispenses that against a diagnosis, and a named firm makes it. The other version is a vial of powder offered online under the same three characters. A 2026 review files it with performance-enhancing drugs (PEDs) marketed as "research compounds", which names a category and describes no contents. Buying IGF-1 therefore means entering one of two unrelated supply chains, and only one of them leaves a record an outsider can read.

Question 2

What is a listing for IGF-1 LR3 offering?

Accepted Answer

Long R3 IGF-1 is a changed molecule, not a brand name for the original one. A 2026 review lists it among the insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)) that appear in online self-administration protocols. The word analogue carries the whole sentence. An analogue shares a family with the original and differs somewhere specific, and the stated point of this difference is to keep the molecule in the blood for longer. So a buyer is not getting a cheaper version of the medicine. They are getting a related compound, and the human record for that compound is the part this page keeps coming back to.

Question 3

Does the trial record travel to that vial?

Accepted Answer

It does not, and this is where most of the muddle around this compound starts. The human evidence belongs to mecasermin. That is a different preparation, from a different maker, with an approval written around one diagnosis. Mecasermin (recombinant human insulin-like growth factor-I [IGF-I]) is approved in the US for the long-term treatment of growth failure in children with severe primary IGF-I deficiency. A 2026 review ranks this family by the evidence behind each member, and the analogues sit at the end of a scale that runs down to a complete absence of human studies. An approval belongs to one named preparation from one named firm, and it does not follow a chemical name onto somebody else's label. Read the consequence rather than the rule. Every success rate, every safety figure and every schedule published for the approved medicine describes material a buyer is not holding.

Question 4

How many different things share the name IGF-1?

Accepted Answer

Three at least, and a certificate that says IGF-1 does not say which. The first is the hormone your own liver makes, which is what a blood test counts. The second is mecasermin, the recombinant human copy of it. The third is mecasermin rinfabate, a complex of equimolar amounts of insulin-like growth factor (IGF)-I and its binding protein IGFBP-3, has been approved by the U.S. Food and Drug Administration on its own terms. Add Long R3 IGF-1 and the market holds four objects behind one abbreviation. A label naming the molecule is not an identity statement until it says which of the four it means. That is checkable, and it costs nothing: ask which analogue is in the vial, then ask the certificate to name it the same way.

Question 5

Where does the approved IGF-1 come from?

Accepted Answer

From a named company, through a named plant, under a filed standard. Tercica, under license from Genentech, has developed and launched mecasermin, recombinant human insulin-like growth factor-1 (rhIGF-1). The binding-protein version has a trail of the same kind. Insmed and Avecia of the UK have signed an agreement for manufacturing mecasermin rinfabate and its components, rhIGF-1 and rhIGFBP-3. Production was to run at Avecia's Advanced Biologics Centre, Billingham, UK, which manufactures recombinant-based medicines and vaccines at the capacity of up to 1000L. Count what that sentence contains. A firm, a site, a town, a manufacturing standard and a stated capacity. A listing for IGF-1 LR3 supplies none of the five, and that gap is the practical difference between the two supplies rather than a difference of tone.

Question 6

How many people is that supply built for?

Accepted Answer

Very few, which is why it is hard to get and easy to misread. A Canadian funding review puts a number on it. In Canada, it is estimated that approximately 5 cases of SPIGFD are diagnosed each year, or 1 case in every 77,000 births, where SPIGFD is severe primary IGF-1 deficiency. The same review set conditions on payment, holding that Increlex should only be reimbursed if prescribed by a pediatric endocrinologist, if it is not prescribed in combination with recombinant growth hormone treatment. A second strand of use is smaller again, with currently available data in the literature comprising more than 30 treated patients worldwide for one group of severe insulin-resistance syndromes. A 2014 review mentions the recent drug shortage with mecasermin. A supply built for a few dozen children is not a supply anybody browses.

Question 7

Is IGF-1 legal to buy?

Accepted Answer

This is the second most searched form of the question, and the honest answer comes in two halves. No source behind this page addresses the statute in any country, because journals and funding reviews do not settle law. What the record does fix is the approval boundary, and that boundary is drawn tightly. The US approval covers growth failure in children with severe primary IGF-I deficiency, and the EU approval covers the same shortfall in children and adolescents. Beyond it, a 2026 review names the absence of regulatory approval for physique- or performance-related indications. Approval and legality are two different questions, and merging them would mean guessing at the one we cannot check. Where the compound stands more broadly is set out on the overview page at the IGF-1 overview.

Question 8

Is there an IGF-1 supplement you can swallow?

Accepted Answer

Nothing in these sources describes an oral preparation of this molecule at all. Every version with a documented history is an injection. Of mecasermin rinfabate, a 2008 review states that it is administered as a once-daily subcutaneous injection, and the recombinant hormone on its own is described as injectable throughout the literature behind this page. There is a reason, and it is not fashion. IGF-1 is a protein, and a protein swallowed whole meets the same machinery that takes apart the protein in food. A capsule labelled IGF-1 is therefore making a claim about absorption that no study covered here has tested. That is a hole in the record rather than a refutation, and it happens to be the hole a buyer is being asked to pay for.

Question 9

Can a certificate of analysis identify a protein?

Accepted Answer

It can get close, and the limits are specific to this molecule rather than general. A certificate usually reports purity from chromatography and a mass figure from spectrometry. For a protein, those two together say that something of roughly the right weight is present and that little else is. What they do not say is whether the chain folded into the right shape, because a misfolded protein weighs exactly what a correct one weighs. They also do not separate a close analogue from the molecule a buyer believes they ordered, and this market holds several. So a clean certificate narrows the question without closing it. The test that would close it is a different kind of test altogether, and the manufacturing literature shows what it looks like.

Question 10

What would a laboratory compare a vial against?

Accepted Answer

A reference preparation, and that is the one thing a buyer cannot get hold of. The 2023 manufacturing paper is plain about it. Purified IGF-1 and LR3 IGF-1 display excellent bioactivity of cell proliferation compared to the standard IGF-1. In other words the makers grew cells, measured how fast they divided, and set the answer beside a known-good preparation of the hormone. That is a functional test rather than a weight. The same paper notes that higher heterologous expression levels of the fusion proteins XynCDBFV-IGF-1 and XynCDBFV-LR3 IGF-1 are achieved by fermentation in a 15-L bioreactor, which is a fact about a process and not about a vial. A certificate reporting mass and purity alone has skipped the only test that asks whether the molecule still works.

Question 11

What happened when IGF-1 was promoted past its evidence?

Accepted Answer

There is a precedent for this in the medical literature, which is unusual and worth having. A 2009 review puts it in a sentence. Promotion of rhIGF-I for treatment of idiopathic short stature has been intensive, with neither data nor rationale suggesting that there might be a better response than has been documented with rhGH. Idiopathic short stature means a child who is short with no cause identified. The same review concludes that it is unlikely that mecasermin will be useful beyond the orphan indications of severe insulin resistance and GH insensitivity. Notice who was making the case, and about what. That was marketing of an approved medicine, inside a regulated system, running ahead of its own evidence. The unregulated side of this market has none of the brakes that system has.

Question 12

Has anyone opened a vial sold as IGF-1 LR3?

Accepted Answer

Not among the research behind this page, and that gap is the most important line here. Retail analyses of this kind exist for other compounds in this market, and these sources carry none for this one. What stands in their place is a statement of uncertainty from the people who meet the consequences. A 2026 review built its advice for doctors around the uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains. So a clinician reading a blood test beside a patient is told to assume the contents of the injection are unknown. A reader choosing what to buy sits in a weaker position than that clinician rather than a stronger one, holding the same unknown without a laboratory to take it to. The documented harm record is gathered at the IGF-1 safety page.

Question 13

What can you check before money changes hands?

Accepted Answer

Less than a listing implies, and more than nothing at all. Four things are checkable in principle. First, which molecule is named, since IGF-1, Long R3 IGF-1 and mecasermin rinfabate are three different objects and a certificate should say which one it tested. Second, whether the batch number on the certificate matches the number printed on the vial, because a certificate for another batch describes another vial. Third, whether the laboratory named on the document will confirm in writing that it wrote the document. Fourth, whether the report gives a method and a date rather than a bare percentage. None of the four settles what is inside the glass. Any one of them that fails, though, settles the purchase without a laboratory being involved at all.

Sourcing IGF-1: what to verify